Kenvue Brands LLC Initiates Class II Recall for TYLENOL Extra Strength Due to Defective Container
Kenvue Brands LLC has initiated a voluntary Class II recall for a specific lot of TYLENOL Extra Strength (Acetaminophen 500mg) due to a defective container. This action, affecting 3,816 bottles distributed nationwide, underscores critical packaging quality control for OTC drugs. Procurement and regulatory teams must assess supply chain vulnerabilities and ensure compliance with FDA standards.
Kenvue Initiates Class II Recall for TYLENOL Extra Strength Due to Container Defect
Kenvue Brands LLC has initiated a voluntary Class II recall for a specific lot of its widely distributed TYLENOL Extra Strength product. This action, identified under recall number D-0121-2026, commenced on October 21, 2025, and remains ongoing. The recall targets Acetaminophen 500mg caplets, specifically 24-count bottles with NDC 50580-378-04, distributed by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division. The core issue driving this recall is a "Defective Container," impacting Lot EJA022, which carries an expiry date of April 30, 2028. A total of 3,816 bottles are affected by this market withdrawal. For procurement directors, this incident highlights the critical importance of scrutinizing the quality and integrity of packaging suppliers, particularly for high-volume over-the-counter (OTC) pharmaceuticals like Acetaminophen. Quality assurance teams must review their incoming material specifications and testing protocols for primary packaging components to proactively identify and prevent similar defects. While the quantity involved is relatively small, the recall of a flagship product like TYLENOL underscores that even seemingly minor packaging flaws can trigger significant regulatory actions, leading to supply chain disruptions and potential reputational damage for the brand.
Supply Chain and Retailer Exposure for Acetaminophen Products
The distribution pattern for the recalled TYLENOL Extra Strength product is U.S. Nationwide, with specific mentions of Colorado, Illinois, Ohio, and Indiana. This broad reach necessitates immediate action from supply chain VPs and business development executives across the retail and pharmaceutical sectors. Kenvue Brands LLC is the recalling firm, while Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division, handled the distribution, clarifying the entities responsible for market presence. Retailers operating in the specified states, and potentially across the broader U.S. market, must conduct prompt inventory checks to identify and quarantine Lot EJA022 of TYLENOL Extra Strength (NDC: 50580-378-04). Failure to effectively remove recalled products from shelves can expose retailers to significant regulatory penalties, consumer safety risks, and severe reputational damage. For procurement teams, this event serves as a crucial reminder to evaluate supplier qualification processes for all packaging materials, emphasizing container integrity and robust manufacturing quality. Even a limited quantity recall for a ubiquitous OTC drug like Acetaminophen can highlight vulnerabilities in the broader supply chain, urging a re-evaluation of risk mitigation strategies for critical components.
Regulatory Context and Implications of a Class II Voluntary Recall
The FDA has classified this event as a Class II recall, indicating that "use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." This classification, while not signifying an immediate life-threatening risk, still mandates prompt and effective market withdrawal. The recall was initiated voluntarily by Kenvue Brands LLC, with initial firm notification conducted via letter, demonstrating a proactive approach to addressing the identified defect. As of the report date, November 5, 2025, the recall status is ongoing. For regulatory affairs heads, this incident reinforces the FDA's consistent vigilance over product quality, extending to packaging integrity for human OTC drugs. It underscores the necessity for pharmaceutical companies to maintain robust quality management systems that encompass all aspects of product manufacturing and packaging. Regulatory teams should ensure their internal recall procedures are well-defined, regularly tested, and fully compliant with FDA guidelines for swift and efficient market withdrawal. While the direct impact on market share for Acetaminophen may be minimal given the limited quantity, the event serves as a critical case study for maintaining consumer trust and regulatory compliance in the highly competitive global chemical and life sciences industry.